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Abstract: Precision oncology is an emerging approach in cancer care. It aims at selecting the optimal 
therapy for the right patient by considering each patient’s unique disease and individual health 
status. In the last years, it has become evident that breast cancer is an extremely heterogeneous 
disease, and therefore, patients need to be appropriately stratified to maximize survival and quality 
of life. Gene-expression tools have already positively assisted clinical decision making by estimating 
the risk of recurrence and the potential benefit from adjuvant chemotherapy. However, these 
approaches need refinement to further reduce the proportion of patients potentially exposed to 
unnecessary chemotherapy. Nuclear magnetic resonance (NMR) metabolomics has demonstrated 
to be an optimal approach for cancer research and has provided significant results in BC, in 
particular for prognostic and stratification purposes. In this review, we give an update on the status 
of NMR-based metabolomic studies for the biochemical characterization and stratification of breast 
cancer patients using different biospecimens (breast tissue, blood serum/plasma, and urine). 
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1. Breast Cancer: Why Precision Oncology? 
Precision medicine, also called personalized medicine, is an emerging approach for 
disease treatment and prevention that takes into account genetics, epigenetics, 
metabolism, environment, and lifestyle of each individual person with the goal to select 
the optimal therapy for the right patient. In oncology, tumor molecular profiling leads to 
the identification of patient specific alterations that could inform about the optimal 
treatments and maximize patient’s survival. 
For several years breast cancer (BC) has been seen as a single clinical entity and 
treated with one general approach. However, now it has become extremely clear that BC 
has to be considered a highly heterogeneous disease with different subclasses. The 
discovery of endocrine receptors, and the understanding that endocrine therapy 
significantly improves outcomes in patients with hormone receptor-positive disease, 
marks the beginning of the target therapy for patients with BC [1–3]. By the late 1990s, it 
was discovered that a subgroup of breast tumors (15–20%) overexpresses the HER2 
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receptor or have HER2 gene amplification. HER2-positive disease had a dismal outcome 
until the development of targeted agents, which has significantly improved outcomes in 
both the (neo)adjuvant [4–8] and the metastatic setting [9,10]. The more recent gene-
expression assays allow clinicians to assess the risk of recurrence in early breast cancer 
(EBC) [11–13], as well as to predict potential benefit from adjuvant chemotherapy [14–17]. 
In many patients found to have a disease with favorable gene-expression profile, 
chemotherapy could be avoided; however, a significant population of EBC patients may 
still be overtreated. Precision oncology aims at identifying the optimal treatment for each 
patient, specifically tailored to each unique cancer profile and to each individual health 
status in order to maximize survival and quality of life. Omics sciences are instrumental 
for this aim (Figure 1). 
 
Figure 1. Precision oncology in a nutshell. 
2. Metabolomics and NMR 
Metabolomics, one of the latest -Omic sciences, entails the comprehensive 
characterization of the ensemble of endogenous and exogenous metabolites presents in a 
biological specimen. Metabolites simultaneously represent the downstream output of the 
genome, the transcriptome, and the proteome, as well as the upstream input from various 
external factors such as environment, lifestyle, diet, and drug exposure [18]. As a 
consequence, in the last few years, metabolomic phenotyping has been extensively 
applied in biomedical research. 
Nuclear Magnetic Resonance spectroscopy (NMR) and mass spectrometry are the 
two most widely used analytical platforms for metabolomics. These two techniques can 
be considered complementary, since the weaknesses of one platform are compensated by 
the strengths of the other [19]. In contrast to the approach typically adopted in mass 
spectrometry, which is focused on target metabolites of interest, NMR metabolomics is 
usually performed using a high-throughput, untargeted approach, which provides a 
complete picture of all metabolites present or quantifiable in the sample above the NMR 
detection limit (concentrations >1μM) [19,20]. To date, NMR metabolomics are 
increasingly used for successful patient stratification in various diseases, and it provided 
unique insights into the fundamental causes of several physiological and 
pathophysiological conditions [21–35]. 
In principle, any biospecimen (i.e., cells, biofluids, and tissues) can be analyzed via 
NMR. The most common biological fluids analyzed by metabolomics are blood 
serum/plasma, urine, and saliva, as they can be collected with low invasiveness, and yield 
plentiful in biological information. Blood derivatives contain all the molecules that are 
secreted by different tissues in response to different physiological stimuli, conditions, or 
stressors [36]. Due to its important systemic role, the concentrations of metabolites in the 
blood are strongly controlled by feedback cycles, so serum/plasma samples are not 
subjected to extreme daily variations and can give information at a systemic level. 
Conversely, urine essentially contains metabolic waste, and thus is more affected by diet, 
environment lifestyle, and drug administration, resulting in significant day-to-day 
Int. J. Mol. Sci. 2021, 22, 4687 3 of 24 
 
 
variability [37]. Saliva is an important physiological fluid that contains a highly complex 
mixture of substances, and it reflects both the systemic status [38] and the local health 
condition of the oral cavity [39]. A number of other local biofluids, such as exhaled breath 
condensate [40–42], cerebrospinal fluid [43,44], amniotic fluid [45], bile [46], synovial fluid 
[47,48], seminal fluid [49], and fecal extracts [50] can also be analyzed to investigate the 
metabolome of specific compartments. Cell lysates, cell growth media, and extracts of 
tissues can also be analyzed [51,52]. Further, the development of high resolution (HR) 1H 
magic angle spinning (MAS) spectra [53] has made viable the acquisition of data on small 
slices of tissue without the need of any extraction or pre-treatment [54–56]. 
Metabolomic fingerprints, as well as the identification and quantification of the most 
abundant metabolites (metabolomic profiling), can be directly obtained by the analysis of 
basic one-dimensional (1D) NMR spectra. 1D NOESY [57], 1H CPMG (Carr–Purcell–
Meiboom–Gill) [58], and 1H diffusion-edited [59] are the pulse sequences most commonly 
used in metabolomics studies. NOESY spectra enables the detection of all molecules 
present in the sample above the NMR detection limit, CPMG spectra allow the selective 
detection of low molecular weight metabolites, whereas diffusion-edited spectra permit 
the observation of only high-molecular weight macromolecules (i.e., proteins and 
lipoproteins). The latter two sequences are particularly useful in biofluids such as 
serum/plasma that contain high amounts of both low and high molecular weight 
compounds. 
Limiting the analysis to the most common biofluids employed in metabolomics, the 
number of molecules detectable and quantifiable by 1D-NMR span from slightly more 
than ten in breath condensate, to more than one hundred in urine. Assignment is mostly 
based on literature data, public databases, such as the de-facto reference standard Human 
Metabolome Database (HMDB) [60–62], commercially available databases and profiling 
software (i.e., ChenomX, AssureNMR). Spectra acquired at high magnetic field and two-
dimensional experiments can be non-routinely employed in selected samples to identify 
unknown metabolites or to confirm NMR assignment [63]. Remarkably, besides small 
metabolites, serum and plasma also contain lipoproteins that with appropriate software 
(i.e., the Bruker IVDr platform) can be finely analyzed to derive, from serum and plasma 
NMR spectra, about 100 different lipid parameters that describe the distribution and 
analytical composition of lipid main fractions and subclasses [64]. This is especially 
important in the lipidomics domain, because the composition of lipoproteins has a strong 
influence on disease development, including BC [65]. 
If applied for population screening, NMR-based metabolomics/lipidomics could 
become a powerful clinical tool in precision oncology. However, to permit experimental 
reproducibility among different studies and/or different collection centers, it is extremely 
important that metabolomic data are collected under rigorously controlled standard 
operating procedures (SOPs). SOPs need to be strictly followed in all the main steps 
involved in the metabolomic work-flow, including sample collection, preanalytical 
processing, and storage [66–68]; NMR spectra recording [69]; and data/metadata 
compilation, description and storage [70]. 
In this review, we will present an overview on the current status of NMR-based 
metabolomics studies in the setting of breast cancer using three different biological 
samples: breast tissue, serum/plasma and urine (Figure 2, Table 1). The translation in the 
clinical practice and the future perspectives for this analytical approach will be also 
examined and discussed. 




Figure 2. Selection of the scientific articles included in this NMR-based metabolomics review. The 
figure shows the workflow of the papers’ selection. 
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Euceda et al. 
2017 [86] 
T 122 BC 
Trondheim 
(Norway) 
122 EBC (IC) 
101 ER+/ 
21 ER− 
122 HER2− 49 600 
Cao et al. 
2012 [87] 
T 30 BC 
Trondheim 
(Norway) 
30 EBC (IC) 
27 ER+/ 
3 ER− 
Not reported 62 600 
Giskeødegår
d et al. 2012 
[88] 
T 98 BC 
Trondheim 
(Norway) 
98 EBC (IC) 
71 ER+/ 
24 ER− 
Not reported 69 600 
Cao et al. 
2012 [89] 
T 85 BC 
Trondheim 
(Norway) 




Not reported 49 600 
Haukaas et 
al. 2016 [90] 
T 228 BC 
Oslo 
(Norway) 







Yoon et al. 
2016 [91] 
T 53 BC 
Seoul 
(South Korea) 






Debik et al. 
2019 [92] 
T, S 118 BC Oslo (Norway) 118 EBC (IC) 
100 ER+/ 
18 ER− 
118 HER2− 48.9 600 
Bro et al. 
2015 [93] 
P 
838 (419 BC; 419 
HC) 
Denmark not reported 
not 
reported 
not reported not reported 600 
Cala et al. 
2018 [94] 
P 58 (29 BC; 29 HC) 
Bogotà 
(Colombia) 








al. 2018 [95] 
P 
602 (206 BC; 396 
HC) 
France not reported 
not 
reported 
not reported 49.3 500 
Louis et al. 
2015[96] 
P 145 (73 BC; 72 HC) 
Hasselt 
(Belgium) 
73 EBC (61 IDC; 
11 ILC; 1 DCIS) 
62 ER+/ 
11 ER− 
not reported 58.5 400 
Richard et 
al. 2017 [97] 
P 65 BC Mons (Belgium) 




not reported 57.6 500 
Suman et al. 
2018 [98] 
P 122 (72 BC; 50 HC) Lucknow (India) not reported 
not 
reported 
not reported 44.3 800 
Vignoli et al. 
2020 [99] 
P 43 BC Aviano (Italy) 43 EBC (IC) 
22 ER+/ 
21 ER− 
43 HER2+ 49 600 
Jobard et al. 
2021 [100] 
P 
1582 (791 BC; 791 
HC) 
Lyon (France) 





Not reported 56.8 600 
Keun at al. 
[101] 






Not reported 59 600 
Asiago et al. 
[102] 2010 
S 56 BC 
Houston (TX, 
USA) 
56 EBC (IC) 
26 ER+/ 
25 ER− 
not reported 53.7 500 
Gu et al. 
2011 [103] 






not reported 55.9 500 
Stebbing et 
al. 2012 [104] 
S 88 BC 
London 
(England) 






Hart et al. 
2017 [105] 
S 699 BC International 









Jiang et al. 
2018[106] 






Jobard et al. 
2017 [107] 
S 79 BC France 79 BC 
not 
reported 
79 HER2+ 50.5 800 
Jobard et al. 
2014 [108] 
S 190 BC Lyon (France) 








et al. 2019 
[109] 
S 115 BC New York (USA) 
28 MBC; 87 EBC 
(IC) 
115 ER+ 115 HER2− 54 600 
Oakman et 
al. 2011 [110] 
S 140 BC Prato (Italy) 







Singh et al. 
2017 [111] 
S 42 (27 BC; 15 HC) Lucknow (India) 27 EBC (IC) 
not 
reported 
not reported 58.6 800 
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Tenori et al. 
2012 [112] 
S 579 BC International 579 MBC 
not 
reported 
not reported not reported 600 
Tenori et al. 
2015 [113] 
S 175 BC New York (USA) 







Wei et al. 
2013 [114] 










al. 2020 [115] 
S 95 (9 BC; 86 HC) 
Wroclaw 
(Poland) 
not reported 9 ER− 9 HER2− 56.67 600 
Flote et al. 
2016 [116] 







al. 2018 [117] 
S 60 BC Norway 







Zhou et al. 
2017 [118] 
S; U 22 (11 BC; 11 HC) Xi’an (China) 




not reported 58 600 
Men at al. 
2020 [119] 
U 




106 EBC (IC) 
not 
reported 
not reported 50.6 600 
Silva et al. 
2019 [120] 






not reported 59 400 
Slupsky et 
al. 2010 [121] 
U 








not reported 56 600 
P: Plasma; S: Serum; U: Urine; T: tissue; BC: breast cancer; HC: healthy controls; IDC: invasive ductal carcinoma; ILC: 
Invasive lobular carcinoma; DCIS: ductal carcinoma in situ; EBC: early breast cancer; MBC: metastatic breast cancer; LABC: 
locally advanced breast cancer; HER2+: human epidermal growth factor receptor 2 positive; RBC: relapsed breast cancer; 
NRBC: non-relapsed breast cancer; TNBC: Triple-negative breast cancer. 
The scientific publications reviewed in the present article were identified by database 
searching in three electronic databases [National Library of Medicine (Medline via 
PubMed®), Web of Science and Scopus] without any restriction on date of publication or 
publication status. Keywords were used as follows: (“metabolomics” OR “metabonomics) 
AND (“NMR” OR “nuclear magnetic resonance spectroscopy”) AND (“breast cancer”) 
AND (“biospecimen”, where biospecimen is tissue or plasma or serum or urine). The 
results of the searches were manually refined in order to remove non pertinent articles. In 
addition, previous systematic reviews were checked to ensure complete data collection. 
3. NMR Metabolomics of Breast Tissue 
High resolution magic angle spinning (HR-MAS) NMR spectroscopy allows the 
quantification of approximately 40 metabolites with a safe, non-destructive method that 
requires minimal sample preparation. Since HR-MAS analyzes intact tissue, it offers the 
potential to further characterize the same specimen via histopathology or utilizing 
transcriptomics and/or proteomics [71,90]. Several studies (Table 2) have shown that HR-
MAS is able to discriminate between malignant and normal breast tissue [72,73], and 
between in-situ and infiltrating carcinoma [74]. Two studies have shown that the 
metabolic profile does not differ significantly based on intra-tumoral location and 
biospecimen type [75,76]. 
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Table 2. List of altered metabolite levels identified in breast tissue of breast cancer patients to study their metabolomic 
profiles. 
Metabolite 
BC vs CTR 
IC vs 
DCIS 
Poor Prognosis vs 
Good Prognosis 









[72] [73] [80] [81] [83] [74] [78] [84] [88] [89] [92] [85] [86] [87] [86] [87] [89] [91] 
Choline   ↑         ↓ ↑  ↓   ↑ 
Phosphatidylcholine/ creatine            ↓       
Total choline ↑ ↑        ↑    ↑  ↓ ↓  
Phosphatidylcholine   ↑ ↑ ↑    ↑   ↓ ↑  ↓  ↓ ↑ 
Glycine  ↑     ↑ ↑ ↑ ↑ ↑ ↓ ↑  ↓  ↓ ↑ 
Scyllo-inositol       ↑            
Myo-inositol      ↓             
Glycerophosphocholine     ↓     ↓  ↓ ↑  ↓ ↓ ↓  
Creatine  ↑       ↓    ↑  ↓    
Glutamine               ↑    
Glutamate             ↑      
Taurine ↑ ↑       ↓ ↓  ↓ ↑  ↓    
Alanine      ↓       ↑  ↓    
Ascorbate  ↑           ↑      
Lactate         ↑ ↑ ↑  ↑  ↑    
Succinate      ↓       ↑  ↓    
Methionine   ↑                
Uridine   ↑                
Lipids   ↓                
Unsatured lipids   ↓                
ATP   ↓                
Glycerophosphocholine/ 
hosphatidylcholine 
    ↓              
Glycerophosphocholine/choline     ↓              
Phosphatidylcholine/ choline     ↑              
Glucose  ↓       ↓    ↓  ↑  ↑  
Glutathione             ↑      
Glycerophosphocholine/choline      ↓             
BC: breast cancer; CTR: control; IC: invasive carcinoma; DCIS: ductal carcinoma in situ; PR: poor responders; GR: good 
responders; SER: signal enhancement ratio; SUV: maximum standardized FDG uptake value. ↑/↓ higher/lower level in the 
first group of each comparison. 
3.1. Correlation with Clinicopathological Factors 
Metabolomics has been shown to be capable of predicting the status of BC prognostic 
factors such as estrogen receptor (ER), progesterone receptor (PR), and axillary lymph 
nodes (Table 3) [77]. In the study of Choi et al. [78], higher choline levels were found to 
correlate with ER-negative and PR-negative tumors. In addition, triple negative status 
(i.e., the absence of ER, PR, and HER2 receptors) was associated with higher choline-to-
creatine and total choline-to-creatine ratios. In a study of Cao et al. [79], the metabolomic 
characterization of triple negative tumors confirmed higher choline levels, but also 
showed an association with lower creatine and glutamine levels, together with higher 
levels of glutamate, glycine, and lactate (Table 3). Tayyari et al. [80] performed a metabolic 
analysis to identify the potential differences between triple negative and hormone 
receptor-positive tumors, within both African-American and Caucasian patients. African-
American patients with triple negative tumors showed higher concentrations of choline, 
glutamine, and glutathione compared to patients with hormone receptor-positive tumors. 
Conversely, Caucasian patients with triple negative tumors showed lower levels of 
glutamine in comparison with African-American patients with triple negative tumors. 
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[77] [78] [79] [82] [77] [78] [78] [79] [78] [53] [83] [78] [79] [80] [82] [83] [83] [78] [84] 
Choline ↓ ↓ ↓  ↓ ↓      ↑ ↑   ↓ ↑   
Choline/creatine            ↑        
Total choline/creatine            ↑        
Phosphatidylcholine/ 
creatine 
        ↑         ↑  
Total choline                  ↑  
Phosphatidylcholine ↑   ↓ ↓   ↓     ↑  ↑ ↑  ↑  
Glycine ↓  ↓ ↓ ↓   ↑     ↑  ↑ ↑ ↑   
Scyllo-inositol    ↓   ↑             
Myo-inositol       ↑         ↑    
Glycerophosphocholine ↓   ↑ ↓      ↑  ↑   ↓    
Creatine ↑    ↓ ↓  ↑     ↓   ↓    
Glutamine   ↑     ↑     ↓       
Glutamate   ↓          ↑       
Taurine ↑   ↑  ↓ ↑        ↓ ↓    
Alanine ↓    ↓   ↓            
Ascorbate ↑    ↓               
Lactate ↓  ↓ ↓ ↓           ↓    
Succinate        ↑            
ATP              ↓      
Lactate/Choline          ↑          
Betaine                ↓    
Glucose                ↑   ↓ 
↑/↓ higher/lower level in the first group of each comparison. 
In the context of HER2-positive tumors, Choi et al. [78] showed a significant 
correlation with higher levels of taurine, scyllo-inositol, and myo-inositol. Moreover, Cao 
et al. [79] described an association with higher concentrations of creatine, succinate, 
glycine and glutamine, and lower concentrations of alanine. 
Choline-containing compounds have been found to be correlated with tumor grade 
and the proliferative marker Ki67. Choi et al. [78] showed that phosphocholine-to-creatine 
ratio was significantly greater in high grade and highly proliferative tumors. In addition, 
Ki67 was associated with increased phosphatidylcholine (PC) and total choline levels. In 
a different study published in 1998, a higher lactate-to-choline ratio was significantly 
correlated with high grade tumors [81]. Axillary lymph node involvement was associated 
with increased glycine and phosphocholine, and reduced betaine and taurine in a study 
by Bathen et al. [82]. 
Sitter et al. [83] showed that higher choline and glycine concentrations are 
characteristic of tumor larger than 2 cm as compared with smaller tumors. A later analysis 
of the same group [84] correlated the metabolic profile of 29 intact BC samples with clinical 
prognosis. Patients with an estimated good prognosis, defined by the absence of disease 
in axillary lymph nodes, primary tumors smaller than 2 cm, and ER- and PR-positive 
disease, were found to have a trend toward a lower concentration of glycine compared to 
those patients with poor prognosis. Moreover, the metabolomic analysis of tissue samples 
with a high proliferation index correlated with low concentrations of glucose. 
3.2. Correlation with Response to Neoadjuvant Therapy 
Metabolic profiling of breast tumor tissue using HR-MAS has been correlated with 
pathological response to neoadjuvant therapy in several studies (Table 2). In the study by 
Choi et al. [85], patients who achieved a pathological complete response (pCR) following 
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neoadjuvant chemotherapy and subsequent surgery were compared with patients 
without a pCR result. No significant differences in the metabolite concentration of pre-
treatment samples were found between responders and non-responders. Moreover, the 
metabolomic profile was not able to predict pCR prior to neoadjuvant treatment in a study 
of Euceda et al. [86]. However, pre-treatment biopsies of responders showed lower levels 
of glucose and higher levels of lactate compared with non-responders. Responders also 
showed an increase in glucose, lactate, and glutamine levels after treatment, and a 
decrease in phosphocholine, choline, and succinate. Cancer cells preferentially switch 
from anaerobic to aerobic glycolysis as result of the Warburg effect [122]. This 
phenomenon is associated with rapid glucose consumption and increased lactate 
production. As such, the lower levels of glucose and higher lactate found in pre-treatment 
samples of responders could reflect a more malignant metabolic profile that paradoxically 
also makes cells more sensitive to chemotherapy. The increase of glucose observed after 
treatment may be an expression of lower glucose consumption. 
Cao et al. [87] showed that the pre-treatment levels of total choline (tCho) were higher 
in patients with tumors responsive to neoadjuvant chemotherapy than those with non-
responsive tumors. Moreover, there was a reduction of tCho levels from pre-treatment to 
post-treatment samples in patients with partial response while this was not observed in 
patients with stable disease. However, these differences were not statistically significant. 
Conversely, glycerophosphorylcholine (GPC) was significantly decreased in post-
treatment samples of patients in the responder group. The tCho signal is involved in 
cellular membrane turnover, therefore a decrease in tCho levels after treatment could 
suggest lower cellular proliferation. 
3.3. Correlation with Survival 
In the study by Giskeodegard et al. [88], the metabolic profile of BC tissue was 
correlated with 5-year survival rates. Higher levels of lactate and glycine were found to 
be associated with worse prognosis in patients with ER-positive BC undergoing upfront 
surgery without any prior treatment. This was not observed in the ER-negative subgroup, 
likely due to the small number of patients (n = 24), whilst also reflecting the metabolic 
differences between ER-positive and ER-negative tumors. 
Similar results were found by Cao et al. [89]. In this study, increased levels of lactate 
on post-treatment tumor samples were associated with worse prognosis (survival < 5 
years), while reduced levels of glycine and choline containing compounds correlated with 
better prognosis. Patients disease-free after five years of follow up also showed increased 
levels of glucose in response to treatment, in comparison with non-survivors. Conversely, 
pre-treatment metabolic analysis of tumor samples gave no prognostic information, 
suggesting that the difference observed between survivors and non-survivors resulted 
from a metabolic response to treatment. In this study, the impact of ER status on metabolic 
profile variations in response to treatment was not investigated. 
Debik et al. [92] analyzed tissue samples from 132 women undergoing neoadjuvant 
chemotherapy. The metabolic profile of tumor biopsies detected during treatment was 
predictive of 5-year survival. In concordance with previous studies, patients with short 
survival had higher lactate and glycine levels in comparison with disease-free patients at 
five years. Increased lactate levels after treatment may reflect the activation of aerobic 
glycolysis and tumor response to hypoxia that led to high tumor aggressiveness and poor 
prognosis. Conversely, decreased glycine and tCho levels in response to treatment may 
be related to altered glycolysis and reduced cell proliferation, as an expression of lower 
disease aggressiveness and better prognosis. 
3.4. Correlation with Transcriptomics and Proteomics 
Metabolomics has been combined with transcriptomics and proteomics to better 
characterize breast tumors and to identify the mechanisms underlying BC heterogeneity. 
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Metabolite, gene expression, and protein data from 228 BC samples were analyzed 
by Haukaas et al. [90]. At the time of sample collection, patients had not received any 
treatment. HR-MAS identified three distinct metabolic clusters (MC1, MC2, and MC3). 
MC1 was characterized by the highest levels of GPC and phosphocholine (pCho); glucose 
was the most concentrated metabolite in MC2; glycine, alanine and lactate were 
predominant in MC3. These three clusters showed different expression of genes involved 
in glycolysis, gluconeogenesis, and glycerophospholipid metabolism, and genes related 
to extracellular matrix. They also expressed different cancer-related proteins. However, 
there were no significant differences in the distribution of PAM50-characterized 
molecular subtypes between the clusters. In a previous study merging transcriptomics 
and metabolomics [71], three subgroups of luminal A tumors with different metabolic 
profile and gene expression were identified. Thus, this supports the premise that 
metabolomics adds relevant information to transcriptomics and proteomics, in turn 
contributing to a more refined subclassification of breast tumors. 
3.5. Correlation with Quantitative Conventional Breast Imaging 
In the study by Yoon et al. [91], 53 BC specimens derived from pre-treatment core 
needle biopsies (CNB) were analyzed with HR-MAS. The metabolomic profile of each 
lesion was then correlated with conventional quantitative breast imaging parameters. It 
was shown that patients with high signal enhancement ratio (SER) at MRI with dynamic 
contrast enhanced (DCE), and with high FDG uptake value (SUV) at PET-CT scan, had 
higher levels of phosphatidylcholine (PC), choline and glycine. Choline was significantly 
correlated with SER, while PC correlated with SUV. Both these correlations were justified 
by the role of choline and PC in cell membrane synthesis, required for tumor cell 
replication and angiogenesis. High SER and SUV levels have been related to poor 
prognostic markers; therefore, choline and PC could be promising metabolites to be used 
to predict poor prognosis. 
4. NMR Metabolomics of Blood Plasma/Serum 
Circulating blood metabolites and lipoproteins may not only reflect the tumor 
metabolism, but more likely may provide a systemic picture of the fine balance between 
the tumor and the host metabolism considering the global physiological and 
immunological conditions of each patient with BC. For all these reasons, several aspects 
of the NMR-based metabolomic signature of BC in plasma/serum have been explored as 
providing novel insight into the molecular aspects of this disease. 
4.1. Characterization of the Metabolomics Profile of BC Patients 
Blood NMR-based metabolomics have been shown to have potential of 
distinguishing patients with BC with respect to healthy controls (HC) with high 
discrimination accuracies [94,95,98,111,115]. The levels of several circulating amino acids, 
and glyco- and lipo-proteins, have been shown to be statistically significantly altered in 
patients with BC (Table 4), implying a disruption of energetic homeostasis and amino acid 
metabolism to support cancer growth and evolution [94,95]. Recently, Jobard et al. [100] 
reported perturbations in circulating plasma metabolites prior to a breast cancer diagnosis 
in a population of 791 breast cancer cases and 791 matched controls. These alterations 
involved particularly histidine, N-acetyl glycoproteins (NAC), glycerol, and ethanol, but 
are statistically significant only in the premenopausal subgroup. 
The metabolome of specific BC molecular subtypes has been also investigated. Study 
of the metabolomic profile of patients with triple-negative BC has further refined the 
molecular characterization of this BC subtype that accounts for 10–22% of all diagnosed 
BC and has the worst survival rate [115]. A recent study on plasma unravels how ER status 
impacts on the metabolomic profiles of patients with HER2-positive BC, with 
metabolomic data also studied in association with levels of circulatory cytokines [99]. 
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Blood metabolomics has also shown how high expression of the receptor for the inositol 
1, 4, 5 Trisphosphate, of which deregulation promotes tumor growth and aggressiveness, 
influences the host system metabolome by increasing lipoprotein content and the levels 
of lactate, lysine, and alanine and by decreasing the levels of pyruvate and glucose [111]. 
Important efforts have been made in order to describe the differences on 
plasma/serum metabolome across EBC and metastatic breast cancer (MBC) 
[97,105,108,110,113]. These two groups of patients can be discriminated by NMR 
metabolomics with high accuracy, and as reported in Table 4, several metabolites showed 
statistically different levels in patients with EBC and MBC, implying a progressive 
disruption and rewiring of several metabolic pathways following the evolution of the 
disease. 
4.2. Blood Metabolomics: Prognosis and Risk of Relapse 
Of interest to clinicians is the potential of metabolomics from a prognostic point of 
view. Metabolomics could provide the ability to discern between patients with EBC at 
high risk of recurrence, and those who may be cured by locoregional therapy alone. In the 
current era of precision medicine, this would represent an invaluable tool for clinicians, 
who may in turn offer more aggressive adjuvant therapies to the former group and 
sparing the latter from treatments whose benefit–risk ratio is poor [123,124]. In 2010, the 
first evidence supporting the usefulness of metabolomics as a potential biomarker of 
recurrence was published by Asiago and coauthors [40]. In this retrospective analysis, a 
PLS-DA model built using 11 metabolites provided a sensitivity of 86% and a specificity 
of 84% in discriminating patients with previous EBC free from disease at six years and 
patients with disease relapse. Of note, 55% of patients were correctly predicted to develop 
recurrence about 13 months before the clinical diagnosis of the same. 
Over the past years our group has pursued this research line establishing a 
reproducible method of quantifying individual serum metabolomic fingerprints and 
demonstrating, in monocentric and multicentric cohorts of patients, its ability to 
accurately discriminate between MBC and EBC [105,109,110,113]. Furthermore, our data 
have shown that patients with EBC classified as “metastatic” on the basis of their 
metabolomic fingerprints presented high risk of disease recurrence. Thus, we 
hypothesized that EBC patients with occult micro-metastatic disease may already have 
features of the metastatic signature in their metabolomic fingerprint, and that this 
signature may be predictive for relapse. Following this approach, in a monocentric cohort 
of ER negative EBC patients we were able to predict cancer relapse with 82% accuracy 
[113]. These results have been reproduced obtaining 71% predictive accuracy by analyzing 
serum samples collected in several centers in South-East Asia, as a part of an unrelated 
Phase III adjuvant trial, from an heterogenous group of patients with mainly ER positive 
EBC [105]. Moreover, we have demonstrated that the serum NMR-based metabolomic 
fingerprinting approach can be effectively utilized to further refining the genomic risk of 
relapse predicted using the OncotypeDX 21-gene expression assay risk recurrence score 
[109]. 
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Table 4. List of altered metabolite levels identified in plasma/serum samples of BC patients to study several aspects of this pathology. 
Metabolite 






MBC vs. EBC REL vs. NR 
Response to Chemotherapy 
PR vs. GR Changes during Treatment 















              ↓         
3-Hydroxybutyrate          ↑ ↑    ↓       ↑  
Acetate          ↑       ↓    ↓↑↑  ↓ 
Acetoacetate ↑          ↑          ↓↑↓ ↑ ↓ 
Acetone ↓  ↓                    ↑ 
Alanine ↓   ↑ ↑     ↑ ↓            ↓ 
Albumin Lysyl                       ↓ 
Apo-B       ↑             ↑    
Arginine  ↑ ↑                     
Betaine           ↓            ↓ 
Cholesterol       ↑             ↑    
Choline          ↑    ↑ ↓        ↓ 
Citrate ↑                 ↑   ↓↓↓  ↓ 
Creatine   ↑       ↑           ↓↑↑  ↓ 
Creatinine   ↑    ↑   ↑           ↓↑↑  ↓ 
Dimethylglutarate                     ↑↓↑   
Ethanol      ↑              ↑    
Formate  ↓        ↑     ↓  ↓    ↓↓↓ ↓  
Glucose ↑ ↑ ↑  ↓   ↑  ↓  ↑ ↑   ↓       ↓ 
Glutamate ↓ ↑   ↑    ↑ ↑ ↑   ↑ ↓ ↑        
Glutamine ↑ ↓ ↑     ↓  ↓         ↑     
Glycerol      ↑     ↑             
Glycerol-derived 
compounds 
  ↓                    ↑ 
Glycerophosphocholine                       ↓ 
Glycine  ↓       ↓ ↑    ↑       ↑↑↓   
Glycoproteins   ↓                     
Histidine      ↑    ↑ ↓  ↓ ↑ ↓   ↓ ↓  ↓↑↑  ↓ 
Isoleucine  ↓        ↑    ↑     ↓ ↑ ↑↓↓  ↓ 
Lactate ↓ ↑  ↑ ↑   ↓ ↑ ↑   ↑ ↑ ↑      ↑↓↓   
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Leucine          ↑    ↑       ↑↓↑ ↑  
Linolenic acid                   ↑     
Lipids  ↑ ↓ ↑ ↑      ↑ ↓ ↑          ↑ 
Lipoproteins  ↑ ↓                    ↑ 
Lysine  ↑ ↑  ↑   ↓    ↑         ↑↓↑  ↓ 
Mannose           ↑            ↑ 
Methanol                       ↓ 
Methionine          ↑           ↓↑↑   
Myo-Inositol                       ↓ 
N-acetyl glycoproteins  ↑   ↓ ↑   ↑  ↑            ↑ 
N-Acetyl-Cysteine            ↑            
N-Acetyl-Glycine               ↓         
Nonanedioic acid               ↓         
Ornitine                     ↓↑↑   
Phenylalanine          ↑ ↑ ↑  ↑  ↑  ↓   ↓↑↑  ↓ 
Phospholipids       ↑             ↑    
Proline          ↑  ↑   ↓        ↓ 
Pyruvate     ↓   ↓   ↑          ↓↓↑   
Threonine                   ↑     
Triglycerides                    ↑    
Tyrosine ↓ ↑        ↑   ↑ ↑ ↑        ↓ 
Unsaturated lipids   ↓                     
Valine  ↓ ↑ ↑          ↑      ↑ ↓↑↑  ↓ 
BC: breast cancer; CTR: control; ER: estrogen receptor; PR: poor responders; GR: good responders; NAC: neoadjuvant chemotherapy; MBC: metastatic BC; 
EBC: early BC; REL: relapse; NR: no relapse. ↑/↓ higher/lower level in the first group of each comparison.
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4.3. Pharmacometabolomics in Breast Cancer Setting 
The application of metabolomics for the study of drug effects and response—the so-
called pharmacometabolomics—can contribute to personalized drug therapy [125], with 
relevant examples of its applications in the setting of BC already having been published. 
The primary aim of metabolomics in this context is to predict which patients will benefit 
most from a specific treatment. First in 2012, our group demonstrated that metabolomics 
may play a role in identifying patients with MBC with HER2-positive disease with a 
greater sensitivity to paclitaxel plus the anti-HER2 agent lapatinib [112]. Jiang and 
colleagues utilized NMR-based pharmacometabolomics to predict response to 
gemcitabine/carboplatin chemotherapy in a population of 29 patients with MBC. Baseline 
serum levels of formate and acetate were identified as potential predictive biomarkers of 
chemotherapy response [106]. In postmenopausal BC women treated with chemotherapy, 
the combination of lactate, alanine, and glucose has been associated with cancer 
progression [104]; moreover, high basal lactate levels were correlated with weight gain in 
postmenopausal women receiving chemotherapy [101]. 
More recently, some metabolomics studies have focused their attention on 
neoadjuvant chemotherapy (NAC). In breast cancer, NAC has become the approach of 
choice for patients with large primary tumors and for locally advanced disease [126]. The 
neoadjuvant approach offers the advantage of downstaging disease and reducing the size 
of tumors prior to surgery, thus making patients with inoperable tumors candidates for 
surgical resection or enabling breast-conserving surgery rather than mastectomy [92,126]. 
However, less than 30% of patients overall show complete pCR to NAC [114], with lower 
rates of response found in ER-positive, HER2-negative disease. Published metabolomic 
studies have been targeted at predicting response to NAC to enable the development of 
personalized treatment protocols, and at characterizing the effects of NAC on the 
metabolome [92,99,107,114]. Plasma/serum metabolomics has been shown to be effective 
in predicting pCR in different NAC regimes [99,114]. Moreover, it has been demonstrated 
that NAC induces relevant changes in patient metabolism during treatment, and that 
these alterations also persist some weeks after the completion of systemic therapy [92,107]. 
In particular, in the study conducted by Jobard et al. [107], the effects of trastuzumab and 
everolimus in combination were associated with alterations that involve several metabolic 
pathways reflecting a systemic effect, particularly on the liver and visceral fat. 
4.4. NMR Lipidomics in Breast Cancer 
Lipidomics represents a relatively new and promising complement to the more 
classical NMR metabolomics. In this particular setting, MS has been for a long time the 
preferred technology, however recent advancements on NMR analysis of blood plasma 
and serum have permitted its wider use. The Bruker IVDr Lipoprotein Subclass Analysis 
platform™ (Bruker Biospin) has enabled a fast and reliable quantification of the main 
lipoprotein parameters and their subfractions. This tool utilizes a chemometric approach 
based on a PLS regression model to perform lipoprotein subclass analysis on 1H NMR 
NOESY spectra [64,127]. 
The lipoproteins analysis via NMR was capable of providing further insights into the 
host metabolic alterations induced by different clinicopathological factors: HDL 
subfraction contents were strongly associated with PgR expression, whereas Ki67 
expression was inversely associated with HDL phospholipids. Conversely no correlation 
was observed between lipoproteins and ER expression. This metabolic information could 
be relevant to characterize breast tumor aggressiveness and prognosis [116]. Moreover, it 
has been observed that women characterized by lower plasma levels of lipoproteins, 
lipids, glycoproteins, acetone, glycerol-derived compounds, and unsaturated lipids 
present a higher risk of developing BC over time [95]. 
Relevant alterations of the lipoproteins’ profiles of BC patients were also observed in 
association with chemotherapy treatments. In particular, alterations of HDL, LDL, VLDL 
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cholesterols and triglycerides were observed during and after treatments. These 
observations were hypothesized to be related to inflammation processes and lipids 
homeostasis [107,117]. 
5. NMR Metabolomics of Urine 
Although urine samples can be easily and non-invasively collected in large volumes, 
and require minimal pre-analytical and analytical preparation, the NMR-based urinary 
metabolome of patients with BC is relatively unexplored to date. Indeed, database 
research located only four published research articles. 
In 2010, Slupsky and coauthors [121] described for the first time the urinary metabolic 
phenotype of a population of 48 patients with BC via NMR. Patients with BC in 
comparison to controls showed significantly lower levels of several metabolites (Table 5). 
However, the BC group was very heterogenous in terms of histologic types (including 
both invasive ductal and lobular carcinoma, as well as ductal carcinoma in situ), lymph 
node status (10 patients had at least one positive lymph node), and age (ranging from 30 
to 86). These factors, if not properly considered, can present significant confounding 
factors. To date, other three research articles (Table 1) have been published [118–120] 
comparing the metabolic profiles of patients with BC to those of healthy controls. These 
studies confirmed the reduction of excretion levels of several metabolites, with the 
exception of citrate which showed a controversial trend (Table 5). The study by Men and 
coauthors [119] also examined the urinary levels of heavy metals, with As, Cd, and Cr 
significantly increased in the urine of patients with BC compared to controls. This finding 
suggests that urine concentrations of heavy metals and BC development could be 
associated. 
Although these published results are thought provoking and point to relevant 
metabolite dysregulations in patients with BC, no large-scale study—mono- or 
multicenter—has been performed to date. Moreover, clinically relevant markers and 
outcomes (i.e., cancer stage, cancer recurrence, response to therapy) have never been 
explored via urine metabolomics. 
Table 5. List of altered metabolite levels identified in urine samples of BC patients with respect to healthy controls. 
Metabolite 
Studies on Urine Samples 
[119] [120] [121] [118] 
2-oxoisocaproate ↓    
3-methylglutarate ↓    
4-cresol sulphate  ↓   
4-hydroxyphenylacetate   ↓  
acetate  ↓ ↓  
acetone  ↓   
alanine ↓ ↓ ↓  
asparagine   ↓  
betaine  ↓   
carnitine  ↓   
choline  ↓   
cis-aconitate  ↓   
citrate  ↓  ↑ 
creatine  ↓ ↓  
creatinine ↓ ↓ ↓  
dimethylamine ↓ ↓ ↓  
ethanolamine   ↓  
formate  ↑ ↓  
glucose   ↓  
glutamate (n-acetylaminoacides) ↓    
glutamine ↓ ↓   
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glycine ↓ ↓   
guanidoacetate  ↓  ↓ 
hippurate ↓  ↓  
histamine ↓    
hypoxanthine  ↓   
isoleucine ↓  ↓  
lactate  ↓ ↓  
leucine ↓  ↓  
levoglucosan   ↓  
lysine ↓    
malonate ↓    
mannitol  ↓   
methylhistidine ↓    
phenylacetylglycine    ↓ 
pyroglutamate   ↓  
pyruvate  ↓   
serine  ↓   
succinate  ↓ ↓  
sucrose   ↓  
taurine ↓ ↓   
threonine  ↓ ↓  
trans-aconitate   ↓  
trigonelline  ↓   
trimethylamine n-oxide ↓ ↓   
uracil   ↓  
urea   ↓  
valine ↓ ↓ ↓  
α-hydroxybutyrate  ↑   
α-hydroxyisobutyrate  ↓   
α-oxoglutarate  ↓   
β-hydroxyisobutyrate ↓    
β-hydroxyisovalerate  ↓   
↑/↓ higher/lower level in the first group of each comparison. 
6. Translation of NMR-Based Metabolomics in Clinics 
This review aimed at highlighting the relevant results obtained using metabolomics 
by NMR in the BC setting and the possible role of this approach in the clinical practice. 
BC is the most common type of cancer and the second most common cause of death 
in women worldwide [128]. Early detection and prompt treatment has been associated 
with a significantly improved prognosis observed over time in patients with BC. 
The serum tumor markers, CEA and CA 15.3, are routinely used in therapy 
monitoring and follow up of patients with BC; conversely, their sensitivity and specificity 
for early diagnosis are poor [129]. Mammography is considered the gold standard in BC 
screening, however it has a sensitivity of 86.9% with relevant variability depending on 
tissue density and age [130]. 
Malignant tumors are characterized by increased gluconeogenesis, glycolysis, and fat 
mobilization, and decreased protein synthesis. The results described in the previous 
paragraphs show that these metabolic changes peculiar to malignant neoplastic change 
can be detected by metabolomics. Metabolomics is able to discriminate between cancer 
and normal breast tissue from the same patient with accuracy, sensitivity, and specificity 
around 90% [73]. Moreover, the metabolite analysis of blood and urine samples from BC 
patients differs significantly from healthy controls [94,95,98,111,115,131,132]. This 
evidence offers potential for the use of metabolomics, a minimally invasive technique, for 
early diagnosis of BC in the general population [133]. 
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BC is a heterogeneous disease with high variability in prognosis and response to 
treatment driven by genetic, epigenetic, and phenotypic differences. The identification of 
the mechanisms underpinning this heterogeneity support the development of new drugs 
targeted to specific subgroup of patients, with the final aim to improve patient outcome. 
Transcriptomics and proteomics have attempted to classify breast tumors according to 
gene expression (intrinsic molecular subtypes—[134]) and protein expression (RPPA 
subtypes—[135]). As shown in the previous sections of this review, metabolomics can 
provide additional information to these -omics, leading to a deeper tumor 
characterization. ER and HER2 status are well estimated by metabolite analysis [79]. In 
addition, metabolomics can identify metabolic clusters within breast tumors, not 
reflecting the intrinsic molecular subtypes, but presenting significant differences in gene 
expression and protein expression profiles, and unique susceptibility to metabolically 
targeted drugs [90]. 
Neoadjuvant chemotherapy is commonly used to treat BC, not only for downsizing 
tumors, but also for the potential to monitor individual drug response. Moreover, in 
selected molecular subtypes, the achievement of a pCR after neoadjuvant treatment 
correlates with excellent long-term outcomes and a lower risk of disease recurrence [136]. 
Currently HER2 positivity, triple negative subtype, high Ki67, and the presence of tumor 
infiltrating lymphocytes (TILs) are the biomarkers most frequently used in recommending 
neoadjuvant chemotherapy. Predicting response to chemotherapy can spare patients with 
unresponsive disease from unnecessary side effects. Metabolomics was shown to play a 
role in predicting response to NAC. 
We have summarized in this review that metabolomic profiling of serum samples 
collected before neoadjuvant chemotherapy was able to predict response in two small 
cohorts of patients. The first cohort was unselected for molecular subtype [114], while the 
second included only HER2-positive breast tumors [137]. The potential role of 
metabolomics in predicting response to treatment was also evaluated on breast tumor 
tissue. This analysis demonstrated that tumor metabolism changed significantly in 
response to neoadjuvant treatment. Metabolomic analysis on post-treatment tissue 
samples was able to discriminate between patients who experienced disease response to 
treatment and those who had non-responsive cancer. However, metabolomic analysis of 
pre-treatment tumor biopsies was not predictive probability of response to chemotherapy 
[85–87]. 
Developing prognostic biomarkers is one of the focuses of metabolomics in BC. 
Clinicopathological features are used to predict the risk of recurrence or development of 
metastatic disease. More recently, gene-expression assays such as Oncotype DX and 
Mammaprint have been introduced in clinical practice to refine risk estimation and 
prediction from adjuvant chemotherapy. However, these assays are time consuming, 
expensive, and can overestimate the risk of recurrence [138]. In addition, they are 
estimated on the primary tumor tissue and cannot identify the presence or absence of 
occult micro-metastases. Metabolomics can contribute to overcoming these limitations. As 
already detailed in the above paragraphs, our group developed a metabolomic score that 
classified patients as high or low risk of recurrent disease on the basis of the degree of 
metabolomic similarities with MBC fingerprints [105,113]. A high metabolomic score 
correlates with increased risk of recurrence and worse disease-free survival. Moreover, 
this metabolomic risk score can be used to sub-stratify the three Oncotype DX risk 
categories [109]. 
However, how far are we now from adopting NMR-based metabolomics as a 
population-wide screening method? The conceptual distance from the present situation 
to this ambitious goal is still wide, but it can be bridged by working in two directions: first 
it is necessary to standardize both the pre-analytical and the analytical procedures. 
Indeed, the biochemical composition of biospecimens is affected by how samples are 
collected, stored, prepared, and analyzed, and consequently differences in these steps can 
be particularly detrimental in multi-center studies [139]. Specifications for pre-
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examination processes for metabolomics in urine, venous blood serum and plasma have 
been already published by CEN (CEN/TS 16945:2016) [140]; however, these 
recommendations are still not universally employed. Secondly, to increase the robustness 
and the reliability of the results already provided, well-planned, large-scale, multicenter, 
population-based studies in which all heterogeneous BC patient groups are well 
represented are needed. NMR-based metabolomics is a fast, high-throughput, robust, and 
reproducible technique, thus moving from the analysis of hundreds to thousands of 
samples is realistically an approachable target [19,141]. 
7. Conclusions 
The NMR-based metabolomics studies presented in this review have demonstrated 
that a metabolic signature of BC exists and can be detected in breast tissue, blood 
serum/plasma, and urine. This approach has the potential to improve early diagnosis of 
BC, to allow early prediction of recurrence and estimating prognosis, and to further 
stratify the heterogenous spectra of BC patients and the individual response to 
(neo)adjuvant treatments. Metabolomics by NMR can play a pivotal role in precision 
oncology and it is mature enough to support, and eventually sub-stratify, the 
identification of risk groups obtained by clinical and genomic tools already in use. 
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